Clinical Trial Update: Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating sequential BCMA/CD19 CAR-T cells for relapsed/refractory autoimmune diseases (including systemic lupus erythematosus and Sjögren's …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome
• Systemic Lupus Erythematosus

Drugs mentioned

• BCMA/CD19 CAR-T cells (BCMA/CD19 chimeric antigen receptor T cells)

Snippet

Sponsor: Essen Biotech | Conditions: Autoimmune Diseases, Systemic Lupus Erythematosus | Phase 1, Phase 2 | Status: RECRUITING